375 related articles for article (PubMed ID: 24857687)
1. Anti-VEGF treatment patterns for neovascular age-related macular degeneration among medicare beneficiaries.
Lad EM; Hammill BG; Qualls LG; Wang F; Cousins SW; Curtis LH
Am J Ophthalmol; 2014 Sep; 158(3):537-43.e2. PubMed ID: 24857687
[TBL] [Abstract][Full Text] [Related]
2. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
[TBL] [Abstract][Full Text] [Related]
3. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries.
Curtis LH; Hammill BG; Qualls LG; DiMartino LD; Wang F; Schulman KA; Cousins SW
Am J Ophthalmol; 2012 Jun; 153(6):1116-24.e1. PubMed ID: 22321802
[TBL] [Abstract][Full Text] [Related]
4. Baseline Predictors for Good Versus Poor Visual Outcomes in the Treatment of Neovascular Age-Related Macular Degeneration With Intravitreal Anti-VEGF Therapy.
Chae B; Jung JJ; Mrejen S; Gallego-Pinazo R; Yannuzzi NA; Patel SN; Chen CY; Marsiglia M; Boddu S; Freund KB
Invest Ophthalmol Vis Sci; 2015 Aug; 56(9):5040-7. PubMed ID: 26237196
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of choroidal neovascularization with indocyanine green angiography in neovascular age-related macular degeneration subjects undergoing intravitreal bevacizumab therapy.
Rush RB; Rush SW; Aragon AV; Ysasaga JE
Am J Ophthalmol; 2014 Aug; 158(2):337-44. PubMed ID: 24844972
[TBL] [Abstract][Full Text] [Related]
7. Comparison of intravitreal bevacizumab treatment between phakic and pseudophakic neovascular age-related macular degeneration.
Ozkaya A; Alkin Z; Perente I; Yuksel K; Baz O; Alagoz C; Yazici AT; Demirok A
Nepal J Ophthalmol; 2014; 6(2):145-52. PubMed ID: 25680245
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
[TBL] [Abstract][Full Text] [Related]
9. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
Funk M; Karl D; Georgopoulos M; Benesch T; Sacu S; Polak K; Zlabinger GJ; Schmidt-Erfurth U
Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
Brechner RJ; Rosenfeld PJ; Babish JD; Caplan S
Am J Ophthalmol; 2011 May; 151(5):887-895.e1. PubMed ID: 21310390
[TBL] [Abstract][Full Text] [Related]
11. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD.
Kloeckener-Gruissem B; Barthelmes D; Labs S; Schindler C; Kurz-Levin M; Michels S; Fleischhauer J; Berger W; Sutter F; Menghini M
Invest Ophthalmol Vis Sci; 2011 Jul; 52(7):4694-702. PubMed ID: 21282580
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal anti-VEGF therapy for neovascular age-related macular degeneration and the risk of stroke.
Cleary CA; Sharaznayan D; Hickey-Dwyer M
Ir Med J; 2011 May; 104(5):146-9. PubMed ID: 21736091
[TBL] [Abstract][Full Text] [Related]
13. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
14. Treatment of neovascular age-related macular degeneration with intravitreal bevacizumab: efficacy of three consecutive monthly injections.
Melamud A; Stinnett S; Fekrat S
Am J Ophthalmol; 2008 Jul; 146(1):91-5. PubMed ID: 18455144
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure.
Kim YJ; Sung KR; Lee KS; Joe SG; Lee JY; Kim JG; Yoon YH
Am J Ophthalmol; 2014 Jun; 157(6):1266-1271.e1. PubMed ID: 24561173
[TBL] [Abstract][Full Text] [Related]
16. Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration.
Cunningham ET; Feiner L; Chung C; Tuomi L; Ehrlich JS
Ophthalmology; 2011 Dec; 118(12):2447-52. PubMed ID: 21872935
[TBL] [Abstract][Full Text] [Related]
17. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration.
Lee SJ; Koh HJ
Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805
[TBL] [Abstract][Full Text] [Related]
18. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
[TBL] [Abstract][Full Text] [Related]
19. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
[TBL] [Abstract][Full Text] [Related]
20. VEGF gene polymorphism and response to intravitreal ranibizumab in neovascular age-related macular degeneration.
Veloso CE; de Almeida LN; Recchia FM; Pelayes D; Nehemy MB
Ophthalmic Res; 2014; 51(1):1-8. PubMed ID: 24157918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
